Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia.

JP, Sharman; SE, Coutre; RR, Furman; BD, Cheson; JM, Pagel; P, Hillmen; JC, Barrientos; AD, Zelenetz; TJ, Kipps; IW, Flinn; P, Ghia; H, Eradat; T, Ervin; N, Lamanna; B, Coiffier; AR, Pettitt; S, Ma; E, Tausch; P, Cramer; J, Huang; S, Mitra; M, Hallek; SM, O'Brien; S, Stilgenbauer

doi:10.1200/jco.18.01460

Public

Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia.

Published in Journal of clinical oncology : official journal of the American Society of Clinical Oncology • Apr 17, 2019

Authors:

Sharman JP

Coutre SE

Furman RR

Abstract

<h4>Purpose</h4>A randomized, double-blind, phase III study of idelalisib (IDELA) plus rituximab versus placebo plus rituximab in patients with relapsed chronic lymphocytic leukemia (CLL) was terminated early because of superior efficacy of the IDELA-plus-rituximab (IDELA/R) arm. Patients in either ...

View

Open Access

Generate AI Take for this paper

Highlights, strengths & weaknesses, commercial applications, and societal impact — written for this paper on demand.

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!